Clinical trial • Phase IV • Neurology

Pregabalin for Peripheral neuropathic pain

Phase IV trial of Pregabalin for Peripheral neuropathic pain. 40 participants.

Overview

Trial Therapeutic Area
Neurology
Trial Disease
Peripheral neuropathic pain
Trial Stage
Phase IV
Drug Modality
Small molecule

Key dates

Initial CTIS Submission Date
01-11-2024
First CTIS Authorization Date
14-11-2024

Trial design

Phase IV trial across 2 sites in Finland.

Target Sample Size
40
Trial Duration For Participant
365

Eligibility

Recruits 40 No vulnerable population selected; participants are adults (age 18-75)..

Vulnerable Population
No vulnerable population selected; participants are adults (age 18-75).

Inclusion criteria

  • {"criterion_text":"-Patients with peripheral painful neuropathy, age 18-75 years, pain is chronic (duration >3 months) and moderate to severe intensity (NRS ≥ 4/10) aiming to recruit 20 patients with at least a moderate sleep disturbance as assessed with ISI-questionnaire (>14) and 20 patients without sleep disturbance."}

Exclusion criteria

  • {"criterion_text":"-Excessive alcohol consumption (>7 doses/week). If the patient uses gabapentinoids (gabapentin or pregabalin), they are discontinued 2 weeks before the study. Psychotic depression, clinically significant bipolar disorder. Contraindications to brain fMRI."}

Endpoints

Primary endpoints

  • {"endpoint_text":"-Pregabalin response to pain. Pain intensity and interference assessed by numeric rating scale","definition_or_measurement_approach":"Pain intensity and interference assessed by numeric rating scale"}

Secondary endpoints

  • {"endpoint_text":"-Pregabalin effect on sleep stages. 1-night Ambulatory Polysomnography (NREM stage III).","definition_or_measurement_approach":"1-night Ambulatory Polysomnography (NREM stage III)"}
  • {"endpoint_text":"-Sleep disturbance associations to brain network connectivity. Brain fMRI for brain network connectivity","definition_or_measurement_approach":"Brain fMRI for brain network connectivity"}
  • {"endpoint_text":"-Sleep disturbance associations to choroid plexus volume in brain fMRI. Brain fMRI for choroid plexus volume measures","definition_or_measurement_approach":"Brain fMRI for choroid plexus volume measures"}
  • {"endpoint_text":"-Pregabalin effect on circadian rhythms. 1-week actigraphy and OURA-ring","definition_or_measurement_approach":"1-week actigraphy and OURA-ring to assess circadian rhythms"}
  • {"endpoint_text":"-Pregabalin effect on body temperature during sleep. 1-night body temperature measurement by iButton","definition_or_measurement_approach":"1-night body temperature measurement by iButton"}

Recruitment

Planned Sample Size
40
Recruitment Window Months
37
Consent Approach
Informed consent obtained from adult participants; a Subject information and informed consent form is listed among study documents.

Geography

Total Number Of Sites
2
Total Number Of Participants
40

Finland

Earliest CTIS Part Ii Submission Date
01-11-2024
Latest Decision Or Authorization Date
14-11-2024
Processing Time Days
13
Number Of Sites
2
Number Of Participants
40

Sites

Site Name
HUS-Yhtymae
Department Name
Neurology
Contact Person Name
Hanna Harno
Contact Person Email
hanna.harno@hus.fi
Site Name
HUS-Yhtymae
Department Name
Neurology
Contact Person Name
Hanna Harno
Contact Person Email
hanna.harno@hus.fi

Sponsor

Primary sponsor

Full Name
HUS-Yhtymae
Organisation Type
Hospital/Clinic/Other health care facility
Country Of Registered Address
Finland

Investigational products

Investigational Product Name
Lyrica 25 mg hard capsules
Active Substance
Pregabalin
Modality
Small molecule
Routes Of Administration
Oral
Route
Oral
Authorisation Status
Authorised
Starting Dose
25 mg
Dose Levels
25 mg
Maximum Dose
600 mg/day
Investigational Product Name
Lyrica 75 mg hard capsules
Active Substance
Pregabalin
Modality
Small molecule
Routes Of Administration
Oral
Route
Oral
Authorisation Status
Authorised
Starting Dose
75 mg
Dose Levels
75 mg
Maximum Dose
600 mg/day
Investigational Product Name
Pregabalin Pfizer 150 mg hard capsules
Active Substance
Pregabalin
Modality
Small molecule
Routes Of Administration
Oral
Route
Oral
Authorisation Status
Authorised
Starting Dose
150 mg
Dose Levels
150 mg
Maximum Dose
600 mg/day

Related trials

Other published trials that may interest you.